Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment

Bibliography

• Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19(6):733-59
   PubMed Web of Science ®Google Scholar
• Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007;86(11):1022-33
   PubMed Web of Science ®Google Scholar
• Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97(12):2692-6
   PubMed Web of Science ®Google Scholar
• Fleisch H, Felix R. Diphosphonates. Calcif Tissue Int 1979;27(2):91-4
   PubMed Web of Science ®Google Scholar
• Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006;38(5):617-27
   PubMed Web of Science ®Google Scholar
• Leu CT, Luegmayr E, Freedman LP, et al. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006;38(5):628-36
   PubMed Web of Science ®Google Scholar
• Lin JH, Chen IW, Deluna FA. Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake. Drug Metab Dispos 1994;22(3):400-5
   PubMed Web of Science ®Google Scholar
• Lin JH, Chen IW, Deluna FA, Hichens M. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther 1993;267(2):670-5
   PubMed Web of Science ®Google Scholar
• Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991;19(5):926-32
   PubMed Web of Science ®Google Scholar
• Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992;20(4):473-8
   PubMed Web of Science ®Google Scholar
• Peter CP, Guy J, Shea M, et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone. J Pharmacol Exp Ther 1996;276(1):271-6
   PubMed Web of Science ®Google Scholar
• Bauss F, Lalla S, Endele R, Hothorn LA. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 2002;29(10):2200-8
   PubMed Web of Science ®Google Scholar
• Endele R, Loew H, Bauss F. Analytical methods for the quantification of ibandronate in body fluids and bone. J Pharm Biomed Anal 2005;39(1-2):246-56
   PubMed Web of Science ®Google Scholar
• King LE, Grynpas MD, Tomlinson G, Vieth R. Pamidronate content and turnover in sternum, vertebral body, and iliac bones of dogs. Bone 1997;20(5):405-11
   PubMed Web of Science ®Google Scholar
• Komatsubara S, Mori S, Mashiba T, et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003;18(3):512-20
   PubMed Web of Science ®Google Scholar
• Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004;19(6):999-1005
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates in bone disease. From the laboratory to the patient. 4th edition. New York: Academic Press; 1990
   Google Scholar
• Lin JH, Chen IW, Deluna FA. On the absorption of alendronate in rats. J Pharm Sci 1994;83(12):1741-6
   PubMed Web of Science ®Google Scholar
• Usui T, Watanabe T, Higuchi S. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug Metab Dispos 1995;23(11):1214-9
   PubMed Web of Science ®Google Scholar
• Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88(6):2095-105
   PubMed Web of Science ®Google Scholar
• Bauss F, Pfister T, Papapoulos S. Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 2008;26(4):406-8
   PubMed Web of Science ®Google Scholar
• Kasting GB, Francis MD. Retention of etidronate in human, dog, and rat. J Bone Miner Res 1992;7(5):513-22
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280(24):2077-82
   PubMed Web of Science ®Google Scholar
• Colon-Emeric CS. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA 2006;296(24):2968-9
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Cheng H, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008 May 16. [Epub ahead of print]
   Google Scholar
• Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008;19(3):365-72
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33(3):301-7
   PubMed Web of Science ®Google Scholar
• Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004;11(6 Pt 1):622-30
   PubMedGoogle Scholar
• Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000;85(4):1492-7
   PubMed Web of Science ®Google Scholar
• Ravn P, Christensen JO, Baumann M, Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 1998;22(5):559-64
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137(11):875-83
   PubMed Web of Science ®Google Scholar
• Wronski TJ, Dann LM, Qi H, Yen CF. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats. Calcif Tissue Int 1993;53(3):210-216
   PubMed Web of Science ®Google Scholar
• Tamura Y, Miyakoshi N, Itoi E, et al. Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats. J Bone Miner Res 2001;16(3):541-9
   PubMed Web of Science ®Google Scholar
• Fuchs RK, Phipps RJ, Burr DB. Recovery of trabecular and cortical bone turnover following discontinuation of Risedronate and Alendronate therapy in ovariectomized rats. J Bone Miner Res 2008;23(10):1689-97
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349(13):1207-15
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349(13):1216-26
   PubMed Web of Science ®Google Scholar
• Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19(5):745-51
   PubMed Web of Science ®Google Scholar
• Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to Teriparatide following therapy with Alendronate or Risedronate. J Clin Endocrinol Metab 2008 Aug 5 [Epub ahead of print]
   Google Scholar
• Gasser JA, Kneissel M, Thomsen JS, Mosekilde L. PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 2000;1(1):53-6
   PubMedGoogle Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007;86(11):1013-21
   PubMed Web of Science ®Google Scholar
• Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35(3):155-60
   PubMed Web of Science ®Google Scholar
• Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66(5):987-94
   PubMed Web of Science ®Google Scholar
• Allen MR. Bisphosphonates and Osteonecrosis of the Jaw: Moving From the ‘Bedside to the Bench’. Cells, Tissues, Organs 2008; In Press
   PubMedGoogle Scholar
• Huja SS, Fernandez SA, Hill KJ, Li Y. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 2006;288(12):1243-9
   PubMedGoogle Scholar
• Garetto LP, Tricker ND. Remodeling of bone surrounding the implant interface. In: Garetto LP, Turner CH, Duncan RL, Burr DB, editors, Bridging the Gap Between Dental & Orthopaedic Implants, 3rd Annual Indiana Conference; Indianapolis, IN 1998
   Google Scholar
• Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2008 Jul 23 [Epub ahead of print]
   PubMedGoogle Scholar
• Plotkin LI, Aguirre JI, Kousteni S, et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005;280(8):7317-25
   PubMed Web of Science ®Google Scholar
• Idris AI, Rojas J, Greig IR, et al. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro Calcif Tissue Int 2008;82(3):191-201
   PubMed Web of Science ®Google Scholar
• Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996;19(3):281-90
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Coxon FP, Ebetino FH, et al. Use of a fluorescent analogue of risedronate to study localization and cellular uptake of bisphosphonates in vivo Bone 2008;42:S85
   Google Scholar
• Kline WF, Matuszewski BK. Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection. J Chromatogr 1992;583(2):183-93
   PubMed Web of Science ®Google Scholar
• King LE, Vieth R. Extraction and measurement of pamidronate from bone samples using automated pre-column derivatization, high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Appl 1996;678(2):325-30
   PubMedGoogle Scholar
• Pan H, Sima M, Kopeckova P, et al. Biodistribution and Pharmacokinetic Studies of Bone-Targeting N-(2-Hydroxypropyl)methacrylamide Copolymer-Alendronate Conjugates. Mol Pharm 2008;5(4):548-58
   PubMed Web of Science ®Google Scholar
• Wang D, Sima M, Mosley RL, et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm 2006;3(6):717-25
   PubMed Web of Science ®Google Scholar
• Wang D, Miller SC, Shlyakhtenko LS, et al. Osteotropic Peptide that differentiates functional domains of the skeleton. Bioconjug Chem 2007;18(5):1375-8
   PubMed Web of Science ®Google Scholar
• Coxon FP, Thompson K, Roelofs AJ, et al. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008;42(5):848-60
   PubMed Web of Science ®Google Scholar
• Wang D, Miller S, Sima M, et al. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 2003;14(5):853-9
   PubMed Web of Science ®Google Scholar
• Kozloff KM, Weissleder R, Mahmood U. Noninvasive optical detection of bone mineral. J Bone Miner Res 2007;22(8):1208-16
   PubMed Web of Science ®Google Scholar